NOMD heads into the back half of August with a story that has two distinct threads — a cluster of insider buying done in May that remains the most striking feature of the ownership picture, and a valuation that stays cheap enough to keep the bull case alive even as the stock trades more than 14% below the consensus price target.
The insider angle is the standout. Between May 11 and May 15, a concentrated wave of buying swept through the register. TOMS Capital — a hedge fund with board representation — bought 700,000 shares across two days at prices between $9.23 and $9.57, committing roughly $6.6 million. CEO Dominic Brisby followed with a $1.47 million purchase of 150,000 shares at $9.79. Independent Director Ian Ashken added 100,000 shares for just under $913,000, and the CFO bought a further 14,731 shares. Net insider buying across the 90-day window comes to roughly 982,000 shares worth $9.3 million. The signal is hard to dismiss: the people closest to the business were putting significant personal capital to work at prices well below where the stock trades today at $11.42, up just under half a percent on the week.
Positioning in the lending market tells a relaxed story. Short interest is a modest 2% of the free float — low enough that shorts are not a meaningful force here. The borrow cost of 0.56% is near its one-month high but still firmly in cheap territory. More tellingly, availability is at 1,512% — more than 15 shares available to borrow for every one currently shorted — which means the lending pool is almost entirely unused. The short score of 34, middling by the ORTEX universe, has actually eased from a recent peak of 37.2 on August 11, consistent with a market that is not building a short thesis on this name. Options are mildly more defensive than usual: the put/call ratio at 0.61 is above its 20-day average of 0.51 but still well within one standard deviation, and nowhere near the 52-week high of 0.86 touched earlier this month. The overall posture is cautious rather than combative.
The Street remains constructive but selective on valuation. The mean price target of $11.78 implies roughly 3% upside from current levels — a thin gap that reflects both the stock's partial recovery from its spring lows and some disagreement on what multiple the business deserves. The bullish anchors are BTIG (Buy, $15 target, reiterated August 14) and Barclays (Overweight, $14 target, raised from $12 in late July) — the Barclays upgrade is notable as it reversed a string of target cuts that ran through early 2026. Deutsche Bank is the outlier, having downgraded to Hold with a $10 target back in late March, a call that looks increasingly stale given the insider activity and the stock's subsequent recovery. The factor picture is mixed: the dividend score ranks in the 89th percentile, supported by a yield above 6%, which provides a meaningful floor argument. EPS momentum is weak — ranked in the 10th to 17th percentile over both 30 and 90 days — but forward earnings yield (EP factor) and an EV/EBITDA around 7x argue that the stock is not expensive relative to history. Price-to-book below 0.55x is particularly low for a branded consumer staples company.
The ownership base reflects the stock's value tilt. Martin Franklin, the co-founder who has long been associated with the business, holds 7.8% of shares. TOMS Capital — now a significant buyer — holds 5.3%. Several value-oriented managers including Boston Partners, Massachusetts Financial Services, and Royce & Associates are among the top 15, and MFS added nearly 500,000 shares in the June quarter. DOMA Perpetual Capital added 489,000 shares over the same period. The register is concentrated in hands that are demonstrably comfortable buying at these levels.
The most recent earnings print, on August 13, produced a 2.9% single-day gain — a clean beat that validated, at least for now, the bull case around new management's pricing and volume strategy. The next event is November 13. Between now and then, the key question is whether volume trends in Western European frozen food continue to improve, and whether Barclays' decision to raise its target proves to be the beginning of a broader analyst re-rating or a premature call.
See the live data behind this article on ORTEX.
Open NOMD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
